rs117280616 (BECN1P2): AMD and Lipoprotein Links
Key takeaways
- This variant is in the BECN1P2 - U3 region, studied in a large genome-wide association study of AMD and blood metabolites.
- Among 325 blood metabolites tested in 72,000+ UK Biobank participants, 84 were significantly linked to AMD, with lipoproteins as the dominant class.
- Depletion of very small VLDL particles in blood was identified as a likely causal factor in AMD, based on Mendelian randomization.
- Evidence comes from a single large study with no replication cohort described; findings should be considered preliminary.
Key takeaways
- This variant is in the BECN1P2 - U3 region, studied in a large genome-wide association study of age-related macular degeneration and blood metabolites.
- Among 325 blood metabolites tested in 72,000+ UK Biobank participants, 84 were significantly linked to AMD, with lipoproteins as the dominant class.
- Depletion of very small VLDL particles in blood was identified as a likely causal factor in AMD, based on Mendelian randomization.
- Evidence comes from a single large study with no replication cohort described; findings should be considered preliminary.
What the research says A genome-wide association study (GWAS) of 325 blood metabolites in 98,316 European-ancestry UK Biobank participants identified 84 metabolic markers significantly associated with age-related macular degeneration (AMD) at a false discovery rate-adjusted threshold (P < 0.05), with lipoprotein subclasses comprising 39% of those associations. A two-sample Mendelian randomization analysis - a method that uses genetic variants as natural experiments to test causal relationships rather than mere correlation - flagged 19 metabolites as likely causally involved in AMD, among them 6 very small very low-density lipoprotein (VLDL) subclasses and a phospholipid-to-total-lipid ratio in medium VLDL. Based on these findings, the authors postulate that depletion of circulating very small VLDL is a likely causal mechanism in AMD development, while age remained the dominant overall risk factor.
Reported associations
- Age-related macular degeneration (AMD): 84 blood metabolites significantly associated (false discovery rate-adjusted P < 0.05) in a cohort of 72,376 UK Biobank donors (1,353 AMD cases, 71,023 controls).
- Very small VLDL subclasses: 6 lipoproteins within the very small VLDL fraction identified as likely causally depleted in AMD patients via Mendelian randomization.
- Phospholipids to total lipid ratio in medium VLDL: identified as a likely causal metabolite for AMD alongside the very small VLDL subclasses.
- AMD risk prediction: In a machine learning classifier built from metabolites, age, and sex, age was the dominant predictive factor, with metabolites contributing a smaller but measurable additional signal.
Evidence quality The primary evidence comes from a large UK Biobank cohort (n=72,376, including 1,353 AMD cases and 71,023 controls) with GWAS coverage of 325 metabolites and multiple-testing correction via false discovery rate adjustment. Causal inference was supported by two-sample Mendelian randomization, which strengthens but does not definitively establish causality. The participant population consisted of European-ancestry individuals, limiting generalizability to other ethnic groups. The available study text does not describe independent replication in a separate cohort. Specific per-variant effect sizes for rs117280616 are not reported in the available study excerpt. Findings should be considered preliminary until replicated.
Lifestyle considerations No lifestyle considerations on file for this variant.
Frequently asked questions
What is the BECN1P2 gene region?
BECN1P2 - U3 is the genomic locus in which rs117280616 is located. The provided research does not describe its specific biological function but places it in the context of a genome-wide study of blood metabolites and age-related macular degeneration.
Is rs117280616 linked to age-related macular degeneration?
This variant is in the BECN1P2 - U3 region and has been studied in the context of a large genome-wide association study that found 84 blood metabolites significantly associated with AMD in over 72,000 UK Biobank participants. The available study excerpt does not report per-variant effect sizes for rs117280616 specifically.
What is VLDL and why does it matter for eye health?
VLDL stands for very low-density lipoprotein, a type of fat-carrying particle circulating in the blood. A genome-wide study found that depletion of very small VLDL subclasses is likely causally linked to age-related macular degeneration, the leading cause of irreversible vision loss in people over 50 in developed countries.
How strong is the evidence connecting lipoproteins to macular degeneration?
A genome-wide study of 72,376 UK Biobank participants used Mendelian randomization - a technique that tests causal relationships using genetic variants as natural experiments - and identified very small VLDL depletion as a likely causal factor in AMD. The evidence comes from one large study; independent replication in additional cohorts would strengthen confidence in the findings.
What does Mendelian randomization mean in AMD research?
Mendelian randomization is a statistical approach that uses genetic variants to test whether a biological factor, such as a blood lipid level, causally affects a disease outcome rather than merely correlating with it. In the study associated with this variant, it was used to support the claim that very small VLDL depletion is likely causal for AMD rather than simply co-occurring with it.